Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19

Cleve Clin J Med. 2020 Nov 2;87(11):659-663. doi: 10.3949/ccjm.87a.ccc015.

Abstract

In COVID-19, respiratory infection with SARS-CoV-2 plus another virus (viral co-infection) or with SARS-CoV-2 plus a bacterial pathogen (combined viral and bacterial pneumonia) has been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral co-infection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in COVID-19. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in COVID-19 should, ideally, take into consideration the overall presentation and the trajectory of illness.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage*
  • Bacteria / classification
  • Bacteria / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods
  • Coinfection* / diagnosis
  • Coinfection* / etiology
  • Coinfection* / therapy
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / therapy
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / epidemiology
  • Coronavirus Infections* / therapy
  • Cross Infection / epidemiology
  • Cross Infection / therapy
  • Diagnosis, Differential
  • Humans
  • Pandemics*
  • Patient Care Management / methods*
  • Pneumonia, Bacterial* / epidemiology
  • Pneumonia, Bacterial* / etiology
  • Pneumonia, Bacterial* / therapy
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / epidemiology
  • Pneumonia, Viral* / therapy
  • Virus Diseases* / epidemiology
  • Virus Diseases* / therapy

Substances

  • Anti-Bacterial Agents